ADAM17 and ovarian carcinoma: Analysis by Kaplan–Meier survival curves of ADAM17 immunostaining at first showed that low ADAM17 H score associated with better survival in ovarian cancer patients undergoing first-line treatment plus bevacizumab, suggesting that association of ADAM17 inhibition with this therapeutic schedule might improve efficacy.